Senescence in Chronic Kidney Disease

Launched by MAYO CLINIC · Jul 27, 2016

Keywords

ClinConnect Summary

The proposed studies will examine cellular senescence and the effect of senolytic therapy on senescent cell burden, frailty, and adipose-derived mesenchymal stem cell function in individuals with diabetic chronic kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 40-80 years
• • 2. Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-45 ml/min/1.73m2
• • 3. Diabetes mellitus and taking diabetes medications
• Exclusion Criteria:
• • 1. Concomitant glomerulonephritis,
• • 2. Nephrotic syndrome,
• • 3. Solid organ transplantation,
• • 4. Autosomal dominant or recessive polycystic kidney disease,
• • 5. Known renovascular disease,
• • 6. Pregnancy,
• • 7. Active immunosuppression therapy,
• • 8. Hemoglobin A1c≥10% at screening,
• • 9. History of active substance abuse (including alcohol) within the past 2 years,
• • 10. Current alcohol abuse (\>3 alcoholic beverages/day or \>21 per week),
• • 11. Body weight \>150 kg or body mass index\>50
• • 12. Human immunodeficiency virus infection
• • 13. Active hepatitis B or C infection
• • 14. Tyrosine kinase inhibitor therapy
• • 15. Known hypersensitivity or allergy to dasatinib or quercetin
• • 16. Inability to give informed consent
• • 17. Uncontrolled systemic lupus erythematosus
• • 18. Uncontrolled pleural/pericardial effusions or ascites
• • 19. New invasive cancer except non-melanoma skin cancers
• • 20. Invasive fungal or viral infection
• • 21. Inability to tolerate oral medications
• • 22. Total bilirubin\>2x upper limit of normal
• • 23. Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
• • 24. Subjects on strong inhibitors of CYP3A4.
• • 25. Subjects on therapeutic doses of anticoagulants (Warfarin (Coumadin);Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa) or Other).
• • 26. Subjects on antiplatelet agents ((Clopidogrel (Plavix); Dipyridamole + Asprin (Aggrenox); Ticagrelor (Brilinta); Prasugrel (Effient); Ticlopidine (Ticlid) or Other) who are unable or unwilling to reduce or hold therapy prior to and during the 3-day drug dosing. Subjects may continue their previous regimen on day 4.
• • 27. Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within 10 days
• • 28. Subjects taking H2-antagonists or proton pump inhibitors and unwilling to discontinue therapy 1 week prior and 2 weeks following enrollment.
• • 29. Corrected QT interval (QTc)\>450 msec
• • 30. Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial.